Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
April 29, 2020

Genentech’s arthritis drug tocilizumab shows promise in Covid-19 trial

Early data from a clinical trial in France has demonstrated encouraging profile of Roche unit Genentech’s rheumatoid arthritis drug tocilizumab (Actemra) to treat seriously ill Covid-19 patients.

The study, which was conducted by the Paris university hospital trust (AP-HP), involved 129 hospitalised patients with moderate or severe viral pneumonia.

Read the full article here

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU